In a clinical study, patients treated with darovasertib demonstrated a 50% reduction in tumor size, highlighting the potential of targeting GNAQ and GNA11 mutations to develop effective treatments for uveal melanoma [166,167,168,169]. This evidence concerns the gene GNA11 and uveal melanoma.